Johnson & Johnson (NYSE:JNJ) Shares Sold by Atlantic Trust LLC

Atlantic Trust LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,967 shares of the company’s stock after selling 3,128 shares during the period. Johnson & Johnson accounts for approximately 2.7% of Atlantic Trust LLC’s portfolio, making the stock its 9th biggest holding. Atlantic Trust LLC’s holdings in Johnson & Johnson were worth $4,135,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Stevens Capital Management LP boosted its stake in shares of Johnson & Johnson by 87.9% during the 2nd quarter. Stevens Capital Management LP now owns 12,320 shares of the company’s stock worth $2,030,000 after acquiring an additional 5,763 shares in the last quarter. Kentucky Retirement Systems purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $25,262,000. Bank of Nova Scotia raised its stake in shares of Johnson & Johnson by 28.3% during the second quarter. Bank of Nova Scotia now owns 1,102,325 shares of the company’s stock valued at $181,597,000 after purchasing an additional 243,435 shares during the period. Bank of Montreal Can boosted its position in Johnson & Johnson by 22.0% in the 2nd quarter. Bank of Montreal Can now owns 7,072,870 shares of the company’s stock valued at $1,162,495,000 after buying an additional 1,276,479 shares during the last quarter. Finally, Quest Investment Management LLC raised its position in shares of Johnson & Johnson by 195.3% in the 2nd quarter. Quest Investment Management LLC now owns 92,207 shares of the company’s stock valued at $15,190,000 after purchasing an additional 60,984 shares in the last quarter. Hedge funds and other institutional investors own 67.29% of the company’s stock.

Shares of NYSE:JNJ traded down $0.43 during trading on Monday, hitting $163.93. 62,098 shares of the company were exchanged, compared to its average volume of 7,089,997. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $133.65 and a 1-year high of $179.92. The business’s 50 day moving average is $171.71 and its 200-day moving average is $167.61. The company has a market capitalization of $431.54 billion, a P/E ratio of 24.72, a price-to-earnings-growth ratio of 2.23 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, topping the consensus estimate of $2.29 by $0.19. The company had revenue of $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The company’s quarterly revenue was up 27.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.67 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th were given a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a yield of 2.59%. Johnson & Johnson’s payout ratio is currently 52.80%.

JNJ has been the topic of a number of research reports. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Morgan Stanley downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a research note on Tuesday, September 7th. Finally, Credit Suisse Group set a $193.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from, Johnson & Johnson currently has a consensus rating of “Buy” and an average price target of $190.38.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.